Quantcast

Latest treatment of multiple sclerosis Stories

2009-04-29 07:00:00

SEATTLE, April 29 /PRNewswire/ -- New analyses of data from the 16-Year Long-term Follow-up study with Betaseron(R) (interferon beta-1b), sponsored by Bayer HealthCare Pharmaceuticals, were presented at the American Academy of Neurology's (AAN) 61st Annual Meeting.

2009-04-24 07:00:00

Toronto Stock Exchange Symbol: MS EDMONTON, April 24 /PRNewswire-FirstCall/ - BioMS Medical Corp (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that Mr.

2009-04-21 11:05:00

Toronto Stock Exchange Symbol: MS EDMONTON, April 21 /PRNewswire-FirstCall/ - BioMS Medical Corp.

2009-04-15 08:46:00

Only 39 Percent of Newly Diagnosed Patients Receive a Drug Within One Year of Their First Diagnosis, According to a New Report from Decision Resources WALTHAM, Mass., April 15 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that surveyed neurologists anticipate that less than 30 percent of their use of emerging oral agents --- Merck Serono's oral cladribine, Novartis/Mitsubishi Pharma's...

2009-04-14 07:00:00

Toronto Stock Exchange Symbol: MS EDMONTON, April 14 /PRNewswire-FirstCall/ - BioMS Medical Corp. (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that the independent Data Safety Monitoring Board (DSMB) for the Company's U.S.

2009-04-13 07:53:50

Patients with multiple sclerosis (MS) may soon have more treatment options for their disease.

2009-03-17 07:00:00

Toronto Stock Exchange Symbol: MS EDMONTON, March 17 /PRNewswire-FirstCall/ - BioMS Medical Corp.

2009-03-16 15:30:00

BELGRADE, March 16 /PRNewswire-FirstCall/ - Hard to Treat Diseases (HTDS) www.htdsmedical.com is pleased to announce that a group of investigators (lead by Professor Mirjana Stojiljkovic) from Department of Neurobiology, Institute for Biological Research "Sinisa Stankovic", University of Belgrade, Serbia, (IBISS group) introduced a novel therapeutic approach in treatment of multiple sclerosis (MS), a severe, currently incurable, human disease.

2009-03-02 16:00:00

Toronto Stock Exchange Symbol: MS EDMONTON, March 2 /PRNewswire-FirstCall/ - BioMS Medical Corp (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), announced that effective on March 16, 2009 the exercise term of 11,500,000 share purchase warrants, each of which entitles the holder to purchase one Class A common share at a price of $5.00 per share, will be extended from March 23, 2009 to December 31, 2009. On March 18, 2008, BioMS Medical's Board of Directors passed a...

2009-02-05 07:00:00

Toronto Stock Exchange Symbol: MS EDMONTON, Feb. 5 /PRNewswire-FirstCall/ - BioMS Medical Corp (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that Mr.


Word of the Day
sipe
  • a slit in a tire to drain away surface water and improve traction.
The word 'sipe' comes from Old English and is related to 'seep'.
Related